Contemporary OB/GYN

CONTINUE TO SITE >

OR WAIT 15 SECS

Why a Women's Health Company?Addressing the Cervical Cancer Screening Disparities GapAdvances in the Testing for Preterm Premature Rupture of MembraneBetter For Women SeriesCervical Cancer & Co-TestingCervical Cancer ScreeningCervical Cancer Screening: Protecting and Improving Health Outcomes of WomenCervical Cancer TodayCombination Regimen of Estradiol and ProgesteroneEndometriosisEnhanced Recovery for Cesarean Deliveries in the United States: Perspectives From the Front Lines – Part 1LARC Provider ToolkitLaser Treatment for GSMMenopauseSurgeryUterine Fibroid

ContraceptionCOVID-19GynecologyLegally SpeakingLife TransitionsObstetricsVulvovaginalWell Woman

All NewsResidents CornerPractice Management

K-CastMedical World NewsQuizzes

Podcasts Videos

Conference CoverageConference Listing

Digital EditionDigital Supplements

CMEJob Board

eNewsletterPrint Subscription

Advertise
Contact Us
Job Board
Editorial
Terms of Use
Privacy Policy
Do Not Sell My Personal Information

© 2021 MJH Life Sciences and Contemporary OB/GYN. All rights reserved.

Spotlight

Why a Women's Health Company?
Addressing the Cervical Cancer Screening Disparities Gap
Advances in the Testing for Preterm Premature Rupture of Membrane
Better For Women Series
Cervical Cancer & Co-Testing
Cervical Cancer Screening
Cervical Cancer Screening: Protecting and Improving Health Outcomes of Women
Cervical Cancer Today
Combination Regimen of Estradiol and Progesterone
Endometriosis
Enhanced Recovery for Cesarean Deliveries in the United States: Perspectives From the Front Lines – Part 1
LARC Provider Toolkit
Laser Treatment for GSM
Menopause
Surgery
Uterine Fibroid

ClinicalSee All >

Contraception
COVID-19
Gynecology
Legally Speaking
Life Transitions
Obstetrics
Vulvovaginal
Well Woman

Advertise
Contact Us
Job Board
Editorial
Terms of Use
Privacy Policy
Do Not Sell My Personal Information

© 2021 MJH Life Sciences^™ and Contemporary OB/GYN. All rights reserved.

Should we consider treating patients with refractory PCOS for infertility

March 1, 2000

No. Safety and cost-effectiveness concerns overshadow the potential benefits

Related Content: